For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation

Pharmaceutics. 2022-01; 
Ruth Galindo, Elena Sánchez-López, María José Gómara, Marta Espina, Miren Ettcheto, Amanda Cano, Isabel Haro, Antoni Camins, María Luisa García
Products/Services Used Details Operation
Biochemicals The coupling reagent, 2-(1H-7-azabenzotriazole-1-yl)-1,1,3,3- tetra-methyluronium hexafluorophosphate methanaminium (HATU) was from Genscript (Piscataway, NJ, USA) Get A Quote

Abstract

Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low water solubility, making its application for the treatment of ocular inflammation difficult. To overcome this drawback, biodegradable nanoparticles incorporating Licochalcone-A have been developed. Additionally, to avoid fast clearance and increase cellular internalization into the ocular tissues, PLGA nanoparticles have been functionalized using PEG and cell penetrating peptides (Tet-1 and B6). To optimize the formulations, a factorial design was carried out and short-term stability of the nanoparticles was studied. Moreover, morphology was also observed by transmission electron microcopy and in vitro drug release... More

Keywords

Licochalcone-A, PLGA, cell-penetrating peptides, nanoparticles, ocular inflammation